KBY Biotech Indexv0.0.34
Search
← Pipeline|Polalemzoparlimab

Polalemzoparlimab

Approved
NOB-2280
By Nobel Ilac
Source: Trial-derived·Trials: 4
Modality
Degrader
MOA
WEE1i
Target
GPRC5D
Pathway
Incretin
Hemophilia AOCDMDD
Development Pipeline
Preclinical
~Jan 2013
→ ~Apr 2014
Phase 1
~Jul 2014
→ ~Oct 2015
Phase 2
~Jan 2016
→ ~Apr 2017
Phase 3
~Jul 2017
→ ~Oct 2018
NDA/BLA
~Jan 2019
→ ~Apr 2020
Approved
Jul 2020
→ Jun 2030
ApprovedCurrent
NCT07982326
2,468 pts·Hemophilia A
2020-07→2030-06·Recruiting
NCT06936187
2,712 pts·MDD
2020-10→2030-05·Active
NCT08362942
817 pts·OCD
2025-01→2027-03·Active
+1 more trial
6,269 total pts3 indications
CompletedCurrentUpcoming
Catalysts (4)
2026-09-246mo awayPh3 Readout· Hemophilia A
2027-03-0111mo awayPh3 Readout· OCD
2030-05-144.1y awayPh3 Readout· MDD
2030-06-254.2y awayPh3 Readout· Hemophilia A
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Approved
Recruit…
Approved
Recruit…
Approved
Active
Approved
Active
Catalysts
Ph3 Readout
2026-09-24 · 6mo away
Hemophilia A
Ph3 Readout
2027-03-01 · 11mo away
OCD
Ph3 Readout
2030-05-14 · 4.1y away
MDD
Ph3 Readout
2030-06-25 · 4.2y away
Hemophilia A
RecruitingActive|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT07982326ApprovedHemophilia ARecruiting2468Mayo
NCT06936187ApprovedMDDActive2712VA
NCT08362942ApprovedOCDActive817EDSS
NCT03361381ApprovedHemophilia ARecruiting272FEV1
Competitors (10)
DrugCompanyPhaseTargetMOA
JNJ-8637Johnson & JohnsonNDA/BLACD20WEE1i
PexatenlimabNovartisPhase 1/2GPRC5DKIF18Ai
MRK-853Merck & CoPhase 1PRMT5WEE1i
RibotuximabMerck & CoPhase 2GPRC5DEZH2i
BMY-9931Bristol-Myers SquibbPhase 1GPRC5DFXIai
NVO-7877Novo NordiskPreclinicalGPRC5DFXIai
DoxafotisoranDaiichi SankyoPhase 1Cl18.2WEE1i
AMG-9654AmgenPhase 2GPRC5DDLL3 ADC
GIL-9227Gilead SciencesPhase 2/3GPRC5DCDK2i
RibozanubrutinibGenmabApprovedGPRC5DTNFi